HIGHLIGHTS
SUMMARY
Vascular endothelial growth factor (VEGF) inhibitors have been the first-line treatment of neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) since their efficacy was first established in the pivotal clinical trials. Studies reported that eyes with nAMD, DMO and RVO received fewer VEGF-inhibitor treatments in routine clinical practice, with inferior outcomes, than those in the clinical trials. Registry reported that the 2-year visual outcomes of nAMD in routine clinical practice improved from +2.7 letters for eyes starting treatment in 2007 to +7.8 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.